Antidiabetic oxazolidinediones and thiazolidinediones

Details for Australian Patent Application No. 2005206540 (hide)

Owner Merck & Co., Inc.

Inventors Dropinski, James F.; Shi, Guo Q.; Meinke, Peter T.; Zhang, Yong

Agent Spruson & Ferguson

Pub. Number AU-B-2005206540

PCT Pub. Number WO2005/070905

Priority 60/537,630 20.01.04 US

Filing date 18 January 2005

Wipo publication date 4 August 2005

Acceptance publication date 8 January 2009

International Classifications

C07D 263/44 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

C07D 277/34 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

Event Publications

27 July 2006 PCT application entered the National Phase

  PCT publication WO2005/070905 Priority application(s): WO2005/070905

8 January 2009 Application Accepted

  Published as AU-B-2005206540

7 May 2009 Standard Patent Sealed

12 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005206541-Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof

2005206536-Fusion polypeptides capable of activating receptors